Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial

Watchlist | Portfolio | Dashboard

Contact

Faster, Cleaner, Better.

quotes
- Price Overview
- Performance Report
charts
- Interactive Chart
- Snapshot Chart
technicals
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Acrivon Therapeutics Inc (ACRV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Notes

Alerts

Watch

Help

Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference GlobeNewswire - Wed Oct 22, 3:15PM CDT

AP3 Generative AI KaiSR model globally assesses drug effects on the entire intracellular protein signaling network for optimal drug design and precision medicine development Favorable ACR-2316 preclinical...

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Wed Oct 1, 3:30PM CDT

WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing...

Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights GlobeNewswire - Wed Aug 13, 3:15PM CDT

Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and ACR-2316...

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights GlobeNewswire - Wed May 14, 3:10PM CDT

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025 GlobeNewswire - Fri Apr 25, 7:00AM CDT

Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer GlobeNewswire - Mon Apr 7, 3:05PM CDT

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results GlobeNewswire - Thu Mar 27, 4:44PM CDT

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates GlobeNewswire - Wed Mar 19, 7:00AM CDT

Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer GlobeNewswire - Wed Feb 5, 7:00AM CST

Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights GlobeNewswire - Wed Nov 13, 2024